Poststroke spasticity: Sequelae and burden on stroke survivors and caregivers

Neurology

Volumn 80, Issue 3 SUPPL.2, 2013, Pages

  Zorowitz, Richard D ^a   Gillard, Patrick J ^b   Brainin, Michael ^c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c DANUBE UNIVERSITY KREMS   (Austria)

^d Landesklinikum Donauregion Tulln   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DANTROLENE; PHENOL;

BARTHEL INDEX; CAREGIVER BURDEN; CEREBROVASCULAR ACCIDENT; DAILY LIFE ACTIVITY; FALLING; HEALTH CARE COST; HEMIPARESIS; HUMAN; HYGIENE; MUSCLE TONE; PAIN; PHYSIOTHERAPY; POSTSTROKE SPASTICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL INTERACTION; SOCIAL SUPPORT; SPASTICITY; SURVIVOR;

EID: 84873674990     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.0b013e3182764c86     Document Type: Review

References (33)

1. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 1997; 6:S21-S35. (Pubitemid 128753037)
2. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: Disordered Motor Control. Miami: Year Book Medical Publishers; 1980:485-494.
3. Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005;27:2-6. (Pubitemid 40124834)
4. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35:134-139. (Pubitemid 38057606)
5. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010;257:1067-1072.
6. Urban PP, Wolf T, Uebele M, et al. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41:2016-2020.
7. Brainin M, Norrving B, Sunnerhagen KS, et al. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications. Int J Stroke 2011;6:42-46.
8. Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008; 15:533-539. (Pubitemid 351677501)
9. WeMove.org. Understanding spasticity. Available at: http://www.wemove. org/survey/WEMOVE-Spasticity-Resear-ch-Report-6-2009.pdf. Accessed February 5, 2012.
10. Welmer AK, von Arbin M, Widén Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006;21:247-253.
11. Doan QV, Brashear A, Gillard PJ, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PMR 2012;4:4-10.
12. Gillard P, Sucharew H, Varon S, et al. The negative impact of spasticity on the health-related quality of life of stroke survivors. Stroke 2012;43:A2472.
13. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009;41:536-544.
14. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221. (Pubitemid 30466027)
15. Zorowitz R, Gillard P, Goren A, et al. The health-related quality of life impact of caring for a patient with post-stroke spasticity. 63rd American Academy of Neurology Annual Meeting; April 16, 2011; Honolulu, Hawaii; P06.010.
16. Bakas T, Champion V, Perkins SM, Farran CJ, Williams LS. Psychometric testing of the revised 15-item Bakas Caregiving Outcomes Scale. Nurs Res 2006;55:346-355. (Pubitemid 44412907)
17. Parag V, Hackett ML, Yapa CM, et al. The impact of stroke on unpaid caregivers: results from the Auckland Regional Community Stroke study, 2002-2003. Cerebrovasc Dis 2008;25: 548-554. (Pubitemid 351861473)
18. Sit JW, Wong TK, Clinton M, Li LS, Fong YM. Stroke care in the home: the impact of social support on the general health of family caregivers. J Clin Nurs 2004;13: 816-824. (Pubitemid 39369685)
19. Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010;41:319-324.
20. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 2001; 15:57-68. (Pubitemid 32800196)
21. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. Available at http://bookshop.rcplondon.ac.uk/content-s/ 6988a14a-1179-4071-8f56-dc2a865f0a43.pdf. Accessed October 27, 2011.
22. Smania N, Picelli A, Munari D, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 2010;46:423-438.
23. Cakar E, Durmus O, Tekin L, Dincer U, Kiralp MZ. The ankle-foot orthosis improves balance and reduces fall risk of chronic spastic hemiparetic patients. Eur J Phys Rehabil Med 2010;46:363-368.
24. Esquenazi A. Falls and fractures in older post-stroke patients with spasticity: consequences and drug treatment considerations. Clin Geriatr 2004;12:27-35.
25. Halpern R, Graham GD, Johnson J, Varon S, Zorowitz RD. Adults' adherence to oral antispasticity medications. Phys Med Rehabil 2010;2(9S):S99 [Poster 219].
26. FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist and fingers. FDA News Release. March 9, 2010. Available at: www.fda.gov/NewsEvents/News-room/PressAnnouncements/2010/ucm203776.htm. Accessed January 4, 2012.
27. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010;26:1983-1992.
28. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13(suppl 4):35-40. (Pubitemid 44748282)
29. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347: 395-400. (Pubitemid 34851831)
30. Bakheit AM, Thilmann AF, Ward AB, et al. A random ized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31: 2402-2406.
31. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;32:259-265.
32. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neuro-toxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 2011;43: 486-492.
33. Bergfeldt U, Skold C, Julin P. Short Form 36 assessed health-related quality of life after focal spasticity therapy. J Rehabil Med 2009;41:279-281.